Insider Transactions in Q2 2024 at Onconova Therapeutics, Inc. (ONTX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,221
-5.35%
|
$0
$0.47 P/Share
|
|
Jun 10
2024
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+11.71%
|
-
|
|
Apr 01
2024
|
Robert Redfield Acting Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+50.0%
|
-
|
|
Apr 01
2024
|
Iain D. Dukes Executive Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
1,645,100
+50.0%
|
-
|
|
Apr 01
2024
|
Iain D. Dukes Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
134,237
+41.74%
|
-
|
|
Apr 01
2024
|
Nikolay Savchuk Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
2,530,632
+50.0%
|
-
|
|
Apr 01
2024
|
Nikolay Savchuk Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
134,237
+41.74%
|
-
|
|
Apr 01
2024
|
Werner Cautreels Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Apr 01
2024
|
Charles David Pauza Chief Science Officer Virology |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+50.0%
|
-
|